No insider purchase over the last 90 days. The latest, by Miotto Neil, was filed 16 Aug 2021.
This page follows insider dealings at UpHealth, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of UpHealth, Inc. in twelve months, the latest record being from 26 August 2024.
The full history, which starts in 2019, counts 4 purchases against 9 sales.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2023 · cache
25 of 76 declarations
UpHealth, Inc. is a U.S.-listed healthcare company traded on the NYSE under the ticker UPH. For French-, Belgian- and Swiss-based investors, the name is best understood as a restructuring story in digital health rather than a straightforward growth compounder. The company’s current form emerged in 2021 through a business-combination process, and its strategy has since been materially reshaped. UpHealth is headquartered operationally in Delray Beach, Florida, United States.
At its inception, UpHealth aimed to build a broad digital-health platform spanning care management software, telehealth infrastructure, and clinical services. Its investor communications and SEC filings describe a business designed to help health plans, healthcare providers, and community-based organizations coordinate care, improve interoperability, and expand access through technology-enabled workflows. Over time, the company also highlighted behavioral health, telehealth, and related service offerings, positioning itself around a “whole person care” model.
The competitive profile has evolved significantly. UpHealth has divested or wound down several of its earlier technology platforms, and its recent public disclosures indicate that it no longer offers its former Virtual Care Infrastructure or Integrated Care Management platforms. Instead, management has refocused the business on behavioral health services, with an emphasis on operational simplification, improved profitability, and balance-sheet flexibility. That makes the equity more suitable for investors who can tolerate execution risk, a changing asset base, and a turnaround-style investment case.
From a product and service perspective, the remaining core is centered on behavioral health care delivery, telehealth-enabled services, and pharmacy or care-continuum support tied to those offerings. UpHealth’s service model is intended to provide a more integrated patient journey across levels of care, from inpatient to outpatient settings, while leveraging technology where possible. Geographically, the business is primarily U.S.-focused, with its operational footprint and customer base centered in the United States, even though the company historically described itself as a global digital-health platform.
Recent milestones matter materially for the investment thesis. The stock resumed trading on the NYSE in November 2023 after a disclosure-related suspension, and UpHealth announced the sale of Cloudbreak Health in March 2024. That transaction was important because it strengthened liquidity and reinforced the company’s pivot toward a simpler, more focused structure. Subsequent corporate updates have emphasized deleveraging, portfolio simplification, and concentration on the behavioral-health business.
Overall, UpHealth remains a highly specialized healthcare situation rather than a traditional operating-company story. The key questions for investors are whether the simplified business can scale sustainably, whether profitability improves, and whether the company can stabilize its strategic direction after several years of portfolio transitions.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2023 | 130.0 m USD | -57.8 m USD | -3.26 USD | 10-K |
| Dec 2022 | 158.8 m USD | -223.0 m USD | -15.17 USD | 10-K |
| Dec 2021 | 123.8 m USD | -341.0 m USD | -31.86 USD | 10-K |
| Dec 2020 | 5.4 m USD | -2.2 m USD | -0.04 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.